VasQ External Support for Arteriovenous Fistula

Not Applicable

Completed

• Conditions: Steal Syndrome; Aneurysm; ESRD; Arterio-Venous Fistula; Renal Failure; Renal Disease; Diabetes Mellitus; Kidney Failure
• Interventions: Device: VasQ

• Registration Number: NCT03242343
• Lead Sponsor: Laminate Medical Technologies

Brief Summary

This is a prospective clinical study of the VasQ external support for arteriovenous fistulas. The device is designed to improve fistula outcomes by optimizing the geometrical configuration of the fistula, influencing hemodynamics, minimizing turbulence and promote laminar flow.

All patients will be implanted with the VasQ device and will be followed up for a duration of 24 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-08-03
• Study First Submitted QC: 2017-08-03
• Study First Posted: 2017-08-08
• Study Start: 2017-11-29
• Primary Completion: 2020-10-08
• Study Completion: 2022-04-03
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-05
• Last Update Posted: 2023-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

1. Main study cohort: Patients referred for creation of a new brachiocephalic fistula who consent to take part in the study and which are not indicated for a more distal fistula per treatment guidelines.

   Supplementary study cohort: Patients referred for creation of a new forearm fistula who consent to take part in the study.

2. Male and female participants.

3. Age 18-80 years.

4. Patients willing and able to attend follow up visits over a period of 24 months.

Exclusion Criteria

1. Patients with the planned index procedure being a revision surgery of an existing fistula.

2. Main study cohort: Target artery smaller than 2.5 mm or larger than 6 mm in inner diameter by preoperative ultrasound.

   Supplementary study cohort: Target artery smaller than 2 mm or larger than 4.1 mm in inner diameter by preoperative ultrasound.

3. Main study cohort: Target vein smaller than 2.5 mm in inner diameter by preoperative ultrasound.

   Supplementary study cohort: Target vein smaller than 2 mm in inner diameter by preoperative ultrasound.

4. Significantly stenotic target vein on the side of surgery (≥50%) as diagnosed on preoperative ultrasound. (Scan should include the area between the planned anastomosis site and the Axillary vein.)

5. Unusual anatomy or vessel dimensions (observed on pre-operative ultrasound or intraoperatively) and which preclude adequate fit of the VasQ.

6. Patients with central venous stenosis or obstruction on the side of surgery.

7. Depth of vein greater than 8 mm (on ultrasound) on side of surgery.

8. Known coagulation disorder.

9. Congestive heart failure NYHA class ≥ 3.

10. Prior steal on the side of surgery.

11. Known allergy to nitinol.

12. Life expectancy less than 30 months.

13. Patients expecting to undergo kidney transplant within 6 months of enrollment.

14. Women of child bearing age without documented current negative pregnancy test.

15. Inability to give consent and/or comply with the study follow up schedule.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
VasQ device implantation	VasQ	Main study cohort: Prospective, multi-center, single-arm, open label, enrolling patients referred to surgical creation of new brachiocephalic fistula (BCF). The VasQ will be applied to the AV fistula in all patients. The primary effectiveness endpoint for this trial will be measured at 6 months and compared to a performance goal (PG). Safety will compare descriptively between AE rates for Steal, Infection, Aneurysm and Seroma. Patients will be followed up for an additional 18 months for a total of 2 years. Additionally, this trial has several secondary endpoints. Supplementary study cohort: 15 patients will be prospectively enrolled which are referred to surgical creation of a new forearm arteriovenous fistula. VasQ will be applied to the AV fistula in all patients. Patients will be followed in the same manner as in the Main study cohort, however, the data will be reported separately and not be part of the analysis sets for the study primary and secondary endpoints.

Primary Outcome Measures

Name	Time	Method
Primary Patency of AVF	6 months post AVF creation	Proportion of patients with freedom from intervention since device placement
Occurrence of safety events	Device implantation to 6 months post AVF creation	The occurrence per patient access related safety events

Trial Locations

Locations (15)

Lutheran Medical Group/Indiana Ohio Heart; 🇺🇸 Fort Wayne, Indiana, United States

Boston Medical Center; 🇺🇸 Boston, Massachusetts, United States

Albany Medical College; 🇺🇸 Albany, New York, United States

Grandview Medical Center; 🇺🇸 Birmingham, Alabama, United States

Saint Francis Medical Center; 🇺🇸 Peoria, Illinois, United States

Arizona Kidney Disease & Hypertension Center; 🇺🇸 Phoenix, Arizona, United States

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Charlotte PA; 🇺🇸 Charlotte, North Carolina, United States

Greenville Health System; 🇺🇸 Greenville, South Carolina, United States

Ohio State University Wexner Meidcal Center; 🇺🇸 Columbus, Ohio, United States

Methodist DeBakey Heart and Vascular Center,The Methodist Hospital; 🇺🇸 Houston, Texas, United States

Cardiothoracic and Vascular Surgeons, P.A.; 🇺🇸 Austin, Texas, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Montefiore Medical Center; 🇺🇸 New York, New York, United States